ARCHIVES

More Patients Get Screened, Colorectal Death Rates Drop

This article is from The Cancer Letter archive.

Vol. 34 No. 7 | July 29, 2011

Download PDF Visit The Full Archive

Related Articles

Trial In Metastatic Disease To Be Unblinded After Regorafenib Meets Primary Endpoint

November 25, 2011

Industry Groups Lobby for Lower Standards for FDA Approval

November 18, 2011

Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial

January 27, 2012

In Brief: Hew Finally Okays New NIH Study Section For Chemical, Environmental Carcinogenesis

March 16, 1979

NIH Limits Increases In Competing Renewals To Biomedical Deflator

August 30, 1991

DOD Seeks to Fund Innovative Research In 438 Million Prostate Cancer Program

August 22, 1997